Acarbose, an antidiabetic drug in use since the 1990s, now intrigues longevity researchers as much as metformin, its better-known cousin. In mice, both molecules extend lifespan in the American Interventions Testing Program (ITP), but their mechanisms, their human evidence and their side effects differ markedly. Here we compare what science has established about acarbose and metformin, who these treatments make sense for, and why neither should be taken without medical advice.
In brief – Acarbose is an antidiabetic drug, an inhibitor of intestinal alpha-glucosidases, that slows the absorption of sugars and blunts blood glucose spikes after meals. In genetically heterogeneous mice, it extends median lifespan by 22% in males and 5% in females (ITP study, Harrison et al., 2014). In humans, the STOP-NIDDM trial showed a 25% reduction in the risk of progression to type 2 diabetes in people with prediabetes, along with a lower cardiovascular risk. Metformin, the other reference antidiabetic, has richer human mortality data but a less marked effect in mice. Neither is a longevity drug in the strict sense: their use remains limited to specific medical indications, under prescription.
What is acarbose?
Acarbose is an inhibitor of intestinal alpha-glucosidases, marketed since 1990 (Glucor in France, Precose in the United States) to treat type 2 diabetes and prediabetes. Unlike metformin, which acts mainly on the liver and muscles, it stays almost entirely in the gut: it slows the breakdown of complex sugars into glucose, which flattens the blood glucose peak that follows a meal. This local mechanism explains both its profile of digestive side effects and the interest it draws in aging research, where repeated glucose spikes are associated with accelerated cellular wear.
The mechanism of action, step by step
Acarbose blocks a family of intestinal enzymes, the alpha-glucosidases, which normally cut starch and disaccharides into absorbable glucose. By slowing this step, it spreads the arrival of glucose in the blood over several hours instead of a sharp peak half an hour after the meal. Three consequences follow:
- Lower post-meal blood glucose, with no risk of hypoglycemia when used alone.
- Less insulin stimulation, so a pancreas that is worked less hard.
- A shift of part of the undigested sugars toward the colon, where they feed the microbiota and change the production of short-chain fatty acids.
This last point clearly sets this drug apart from metformin. A microbiota study in treated mice revealed changes in gut flora and in the production of propionate and butyrate that coincide with their longer lifespan (Smith et al., 2019). Metformin, for its part, acts first in the liver by curbing glucose production and activates AMPK, a cellular energy sensor involved in several mechanisms of aging.
What the science says about longevity
The American Interventions Testing Program (ITP), which tests molecules on genetically heterogeneous mice in three laboratories at once, has evaluated acarbose and metformin among some thirty compounds. The results for the two molecules do not look alike.
In mice, acarbose extended median lifespan by 22% in males and 5% in females (Harrison et al., 2014). A second cohort confirmed this effect at three different doses, with gains of 16 to 17% in males (Harrison et al., 2019). Combined with rapamycin, the molecule produced a survival benefit in males greater than that of rapamycin alone, a sign that the two treatments act at least partly through distinct pathways (Strong et al., 2022). This male advantage remains unexplained: it is not linked to body weight, which actually drops more in females.
In humans, the STOP-NIDDM trial (1429 patients with prediabetes followed for 3.3 years on average) showed that acarbose reduces the risk of progression to type 2 diabetes by 25% compared with placebo (Chiasson et al., 2002). A further analysis of the same trial measured a 49% reduction in the risk of a major cardiovascular event and a 34% reduction in the risk of new-onset hypertension (Chiasson et al., 2003). No human trial, however, has measured longer life expectancy on this treatment: these results remain intermediate markers, blood glucose, blood pressure, cardiovascular events, not direct proof of longevity in humans.
Metformin rests on a different body of evidence. Its effect in mice is more modest in the ITP, but in cohorts of people with diabetes it is associated with mortality comparable to, or even lower than, that of matched non-diabetic controls (Bannister et al., 2014). A meta-analysis covering several cohorts confirmed a reduction in all-cause mortality associated with metformin, independent of its effect on blood glucose (Campbell et al., 2017). On this basis, the TAME trial (Targeting Aging with Metformin) was designed to test the molecule directly on aging in non-diabetic people (Barzilai et al., 2016). Its full funding is still pending and the trial has not yet delivered results.
Acarbose vs metformin: the comparison
The choice between the two molecules depends on metabolic profile, digestive tolerance and the medical indication, not on a general longevity ranking. The table sums up the differences established by research.
| Criterion | Acarbose | Metformin |
|---|---|---|
| Main mechanism | Slows the intestinal absorption of sugars | Reduces hepatic glucose production, activates AMPK |
| Effect on lifespan in mice (ITP) | +22% in males, +5% in females | More modest effect, not confirmed in all ITP protocols |
| Strongest human evidence | STOP-NIDDM trial: 25% less progression to diabetes | Observational mortality cohorts, TAME trial in preparation |
| Common side effects | Flatulence, diarrhea in about 30% of patients at the start | Digestive upset, vitamin B12 deficiency in the long term |
| Interaction with the microbiota | Marked: undigested sugars fermented in the colon | Moderate: gut flora is also modified |
| Status in France | Prescription only, prescribed less often than before | Prescription only, reference treatment for type 2 diabetes |
In practice: who acarbose is for
Acarbose remains first and foremost a treatment for type 2 diabetes and for prediabetes confirmed by an oral glucose tolerance test, not an over-the-counter anti-aging product. In France, around 3.8 million people take medication for type 2 diabetes, and metformin remains the first-line treatment, in line with what the World Health Organization describes in its guidance on diabetes care (WHO fact sheet). Acarbose is prescribed as a second- or third-line option, often after metformin, especially in people who tolerate it poorly or who mainly show post-meal glucose spikes rather than high fasting glucose. People with insulin resistance but no confirmed diabetes are not a recognized indication for acarbose outside a medical setting.
Our dedicated article details the scientific evidence on metformin and longevity, the molecule that remains the first-line reference. Among natural AMPK activators, berberine is sometimes presented as an over-the-counter alternative, but its evidence of efficacy remains weaker than that of prescription metformin. Our Deregulated nutrient sensing pillar gathers our other articles on glucose metabolism and longevity.
Protocol, dosing and precautions
Acarbose is taken at the very start of each main meal, the tablet swallowed with the first mouthfuls so that it acts when carbohydrates reach the intestine. The dose is increased gradually over several weeks to limit digestive upset, a principle shared by many treatments that alter the microbiota.
- Never correct a suspected hypoglycemia with ordinary sugar: on this treatment, only pure glucose remains effective, because the drug blocks precisely the breakdown of other sugars.
- Avoid combining this drug with metformin or berberine without medical supervision: stacking several molecules that act on blood glucose raises the risk of digestive upset and requires laboratory monitoring.
- Report any inflammatory bowel disease, hernia or severe kidney failure: acarbose is contraindicated or not recommended in these situations.
No data justify taking this drug as a non-diabetic person for the sole purpose of slowing aging. The effects seen in mice concern animals followed under strict experimental conditions, with dosing and monitoring that no self-medication protocol can reproduce.
Frequently asked questions
Acarbose or metformin: which one should you choose for longevity?
Neither is validated as a longevity treatment in humans. Metformin has more mortality data and is the subject of the TAME trial. Acarbose shows a more marked effect in male mice and cardiovascular benefits demonstrated in the STOP-NIDDM trial. The clinical choice depends on metabolic profile and digestive tolerance, not on an established longevity ranking.
Why does acarbose extend the lifespan of male mice more than that of females?
ITP researchers cannot explain it yet. The gap, 22% versus 5%, is not linked to body weight, which actually drops more in females receiving this treatment. This difference between the sexes also appears with other molecules tested by the same program, such as 17-alpha-estradiol, which suggests a biological mechanism still poorly understood rather than an experimental artifact.
Can acarbose replace metformin?
No, not without medical advice. The two molecules have different mechanisms and are sometimes prescribed together when diabetes is poorly controlled. Switching an antidiabetic treatment is a medical decision based on each patient’s own blood glucose, kidney function and digestive tolerance.
What are the most common side effects of acarbose?
Digestive upset (flatulence, diarrhea, bloating) affects about 30% of patients at the start of treatment, caused by undigested sugar fermenting in the colon. These effects usually decrease with a gradual increase in dose and often ease after a few weeks.
Does the microbiota play a role in the effects of acarbose?
Yes. By blocking the digestion of part of the sugars, acarbose shifts them toward the colon, where they change the composition of the microbiota and the production of short-chain fatty acids such as propionate. A mouse study links these changes in gut flora to the longer lifespan seen on treatment, though the causal link is not fully established.
Medical disclaimer. Acarbose and metformin are prescription drugs, reserved for the treatment of diabetes and prediabetes diagnosed by a healthcare professional. These data come from animal studies and clinical trials conducted in people with diabetes or prediabetes: they do not constitute proof of efficacy against aging in a healthy person. They must never justify self-medication, off-label use or stopping an ongoing treatment. Any decision about these drugs or any other molecule taken for metabolic purposes must be made with a physician, taking into account the contraindications (inflammatory bowel disease, severe kidney failure, pregnancy) and appropriate laboratory monitoring.
